retatrutide clinical trial phase retatrutide Eli Lilly's 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments retatrutide clinical trials phase 2

Is daily dosing with Saxenda or weekly dosing with Ozempic easier

AHI reduction of 32% average with 15% weight loss CPAP discontinuation possible for 25 to 40% of users achieving 20%+ weight loss Oxygen saturation improvements averaging 4 to 6 percentage points Snoring reduction reported by 78% of users losing 30+ pounds Faster Sleep Onset Many users report falling asleep more quickly once they move past the initial weeks of treatment

They have also exposed a structural affordability problem

Evidence from weight loss research suggests this hormonal shift may partially offset the appetite-suppressing effects of retatrutide, particularly during periods of significant weight loss

Consumer platforms like Weight Watchers and Noom now integrate GLP-1 prescribing into coaching and nutrition programs, reframing them as part of holistic lifestyle care

There was concern among potential plaintiffs at first that the court would set high standards for granting injunctions, but that doesnt seem to be happening